Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI versus tiotropium in symptomatic COPD previously treated with tiotropium
2012-005007-41Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Umeclidinium + vilanterol with Tiotropium (2 arms). Primary endpoint: Trough FEV1 on Day 85. Started Apr 2013; status: completed.
02
Drugs
umeclidiniumvilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-005007-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005007-41.